| Feb 4 |
Relay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology Day
|
| Jan 22 |
Relay Therapeutics (RLAY) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
|
| Jan 21 |
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
|
| Jan 14 |
We Think Relay Therapeutics (NASDAQ:RLAY) Can Easily Afford To Drive Business Growth
|
| Jan 6 |
SoftBank’s Son Is Poised for Another IPO Windfall in 2021
|
| Jan 6 |
Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
|
| Dec 17 |
Is RLAY A Good Stock To Buy Now?
|
| Dec 14 |
Relay Therapeutics inks deal for RLY-1971 with Genentech
|
| Dec 14 |
Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971
|
| Nov 25 |
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
|
| Nov 18 |
The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted
|
| Nov 12 |
Relay Therapeutics reports Q3 results
|
| Nov 12 |
Relay Therapeutics Reports Third Quarter 2020 Financial Results
|
| Oct 16 |
Are Insiders Buying Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock?
|
| Oct 3 |
These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference
|
| Sep 23 |
Relay Therapeutics rallies 7% on EcoR1 pitch
|
| Sep 21 |
51 Stocks Moving In Monday's Mid-Day Session
|
| Sep 7 |
Relay Therapeutics: Heavily Backed Biotech Brains Trust Looks A Long-Term Buy
|
| Sep 4 |
Dosing underway in Relay Therapeutics' first-in-human RLY-4008 trial
|
| Sep 3 |
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor
|
| Aug 27 |
Relay Therapeutics EPS misses by $5.03
|
| Aug 27 |
Relay Therapeutics Reports Second Quarter 2020 Financial Results
|
